SNCB

Chr 5q35.2

synuclein beta

MANE:: ENST00000393693.7

OMIM: 602569 ↗NCBI: 6620 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

SNCB · Q16143

v62025-08-01

Predicted Aligned Error matrix for SNCB — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

61.5/ 100

Low

134 residues

Confidence breakdown

Very high(≥ 90)1%
Confident(70–90)34%
Low(50–70)28%
Very low(< 50)37%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Moderate Evidence (Amber)

Adult onset neurodegenerative disorder
Unknown
Early onset dementia (encompassing fronto-temporal dementia and prion disease)

Disease associations (Open Targets)

neurodegenerative disease
0.47
Lewy body dementia
0.44
intracranial hemorrhage
0.24
Alzheimer disease
0.09
glioblastoma
0.05
connective tissue disorder
0.04
central nervous system cancer
0.04
androgen insensitivity syndrome
0.04
atypical teratoid rhabdoid tumor
0.03
dementia
0.03

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Beta-synuclein

Non-amyloid component of senile plaques found in Alzheimer disease. Could act as a regulator of SNCA aggregation process. Protects neurons from staurosporine and 6-hydroxy dopamine (6OHDA)-stimulated caspase activation in a p53/TP53-dependent manner. Contributes to restore the SNCA anti-apoptotic function abolished by 6OHDA. Not found in the Lewy bodies associated with Parkinson disease